Janux Therapeutics, Inc. $JANX Shares Sold by Orbimed Advisors LLC

Orbimed Advisors LLC lessened its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 49.7% during the 1st quarter, HoldingsChannel.com reports. The fund owned 983,600 shares of the company’s stock after selling 970,826 shares during the quarter. Orbimed Advisors LLC’s holdings in Janux Therapeutics were worth $13,672,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of JANX. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Janux Therapeutics during the 4th quarter worth approximately $34,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Janux Therapeutics in the 4th quarter worth approximately $51,000. Osaic Holdings Inc. lifted its stake in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after purchasing an additional 3,037 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Janux Therapeutics in the fourth quarter valued at approximately $137,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the sale, the insider directly owned 75,941 shares in the company, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $14.17, for a total value of $28,878.46. Following the completion of the sale, the vice president directly owned 32,270 shares in the company, valued at $457,265.90. This trade represents a 5.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.90% of the company’s stock.

Janux Therapeutics Price Performance

Shares of JANX stock opened at $15.33 on Monday. The business’s fifty day moving average price is $14.81 and its 200 day moving average price is $14.33. The firm has a market capitalization of $934.82 million, a PE ratio of -8.33 and a beta of 2.52. Janux Therapeutics, Inc. has a 1-year low of $12.12 and a 1-year high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million for the quarter, compared to analysts’ expectations of $4.36 million. Equities research analysts expect that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the company. Wedbush lowered their target price on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Barclays downgraded Janux Therapeutics from an “overweight” rating to an “underweight” rating and decreased their price objective for the company from $29.00 to $14.00 in a report on Monday, April 20th. Piper Sandler lowered their price target on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Guggenheim lowered their price objective on shares of Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $38.08.

Janux Therapeutics Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.